Immune checkpoint inhibition for the treatment of mesothelioma

References

• Odgerel CO, Takahashi K, Sorahan T, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017 Dec;74(12):851–858.
   PubMed Web of Science ®Google Scholar
• Mensi C, Riboldi L, De Matteis S, et al. Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure. Environ Int. 2015 Jan;74:191–199.
   PubMed Web of Science ®Google Scholar
• Harper M, Butler C, Berry D, et al. Where occupation and environment overlap: US forest service worker exposure to Libby Amphibole fibers. J Occup Environ Hyg. 2015;12(5):D47–53.
   PubMed Web of Science ®Google Scholar
• Le GV, Takahashi K, Park EK, et al. Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology. 2011 Jul;16(5):767–775.
   PubMed Web of Science ®Google Scholar
• Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016 Jun;10(3):275–288.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483): 397–408. Jul 30-Aug 5.
   PubMed Web of Science ®Google Scholar
• Segal A, Sterrett GF, Frost FA, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013 Jan;45(1):44–48.
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018 Jan;142(1):89–108.
   PubMed Web of Science ®Google Scholar
• Nelson DB, Rice DC, Niu J, et al. Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol. 2017 Oct 10;35(29):3354–3362.
   PubMed Web of Science ®Google Scholar
• Lim E, investigators oboM-. A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study. Lung Cancer. 2016;91(Suppl 1):S71.
   Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011 Aug;12(8):763–772.
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013 Dec;5(6):E254–307.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
   PubMed Web of Science ®Google Scholar
• van Meerbeeck J, Manegold C, Gaafar R, et al. A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC lung cancer group and NCIC. Proc Am Soc Clin Oncol. 2004;23(abstr 7021).
   Google Scholar
• Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J clin oncol. 2006 Mar 20;24(9):1443–1448.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer. 2008 Jul 8;99(1):51–56.
   PubMed Web of Science ®Google Scholar
• Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009 May;64(2):211–218.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414.
   PubMed Web of Science ®Google Scholar
• Zucali PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar;75(3):360–367.
   PubMed Web of Science ®Google Scholar
• Bagia M, Nowak AK. Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Oncol. 2011 Jun;12(2):149–162.
   PubMed Web of Science ®Google Scholar
• Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med. 1993 Dec;23(6):683–687.
   PubMedGoogle Scholar
• Davidson JA, Musk AW, Wood BR, et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother. 1998 Sep;21(5):389–398.
   PubMed Web of Science ®Google Scholar
• Powell A, Creaney J, Broomfield S, et al. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer. 2006;52(2):189–197.
   PubMed Web of Science ®Google Scholar
• Stevenson J, Kindler HL, Schwed D, et al. A Phase II trial of anti-TGFbeta monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma. International Mesothelioma Interest Group 10th International Conference; 2010; Kyoto, Japan. p. S18–2.
   Google Scholar
• Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001 May;32(2):197–201.
   PubMed Web of Science ®Google Scholar
• Robinson C, Callow M, Stevenson S, et al. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.[see comment]. Am J Respir Cell Mol Biol. 2000 May;22(5):550–556.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006–2017.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected Stage III melanoma. N Engl J Med. 2018 May 10;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-Line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017 Jun 22;376(25):2415–2426.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–2229.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104–1111.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301–309.
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 Sep;18(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017 May;18(5):623–630.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018 Jun;14.
   Google Scholar
• Calabro L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018 Jun 6;6:451–460.
   PubMed Web of Science ®Google Scholar
• Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019 Mar 7;(3):260–270.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019 Feb;20(2):239–253.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 2002 Apr 15;62(8):2353–2358.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003 May 15;170(10):4905–4913.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003 Aug 1;63(15):4490–4496.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–1701.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Cook AM, McDonnell AM, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015 Dec;26(12):2483–2490.
   PubMed Web of Science ®Google Scholar
• Nowak A, Kok P, Lesterhuis W, et al. OA08.02 DREAM - A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result. J Thorac Oncol. 2018;13(10):S338–S39. 2018/12/27.
   Web of Science ®Google Scholar
• Cedres S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10(3):e0121071.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul;9(7):1036–1040.
   PubMed Web of Science ®Google Scholar
• Thapa B, Salcedo A, Lin X, et al. The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol. 2017 May;12(5):850–859.
   PubMed Web of Science ®Google Scholar
• Combaz-Lair C, Galateau-Salle F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9–18.
   PubMed Web of Science ®Google Scholar
• Nguyen BH, Montgomery R, Fadia M, et al. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol. 2018 Feb;14(1):69–73.
   PubMed Web of Science ®Google Scholar
• Pasello G, Zago G, Lunardi F, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018 May 1;29(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Tallon de Lara P, Cecconi V, Hiltbrunner S, et al. Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. Clin Cancer Res. 2018 Dec 15;24(24):6345–6354.
   PubMed Web of Science ®Google Scholar
• Patil NS, Righi L, Koeppen H, et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol. 2018 Jan;13(1):124–133.
   PubMed Web of Science ®Google Scholar
• Lee HS, Jang HJ, Choi JM, et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 Apr 5;3:7.
   Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 4;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016 Apr;48(4):407–416.
   PubMed Web of Science ®Google Scholar
• Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018 Oct;15.
   Google Scholar
• Mansfield AS, Peikert T, Smadbeck JB et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14(2):276–287.
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1–15.
   PubMed Web of Science ®Google Scholar
• Arulananda S, Thapa B, Walkiewicz M, et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018 Oct;13(10):1588–1594.
   PubMed Web of Science ®Google Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2018 Jan;118(2):e5.
   PubMed Web of Science ®Google Scholar
• Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008 Apr;135(4):823–829.
   PubMed Web of Science ®Google Scholar
• Chee SJ, Lopez M, Mellows T, et al. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br J Cancer. 2017;117:1341.
   PubMed Web of Science ®Google Scholar
• Ujiie H, Kadota K, Nitadori JI, et al. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015 Jun;4(6):e1009285.
   PubMed Web of Science ®Google Scholar
• Yamada N, Oizumi S, Kikuchi E, et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010 Oct;59(10):1543–1549.
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Maker AV. Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 2017 Mar;24(3):134–140.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 Aug;560(7718):382–386.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008 Sep;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Chattopadhyay R, Kato S, et al. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res. 2017 Oct 1;77(19):5419–5427.
   PubMed Web of Science ®Google Scholar
• Schwaederle MC, Patel SP, Husain H, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017 Sep 1;23(17):5101–5111.
   PubMed Web of Science ®Google Scholar
• Raja R, Kuziora M, Brohawn PZ, et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018 Dec 15;24(24):6212–6222.
   PubMed Web of Science ®Google Scholar
• Kumar S, Guleria R, Singh V, et al. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 2010 Oct;36(4):885–892.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Velculescu VE, Pritchard TS, et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2(1):42.
   PubMedGoogle Scholar
• Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015 Aug;26(8):1715–1722.
   PubMed Web of Science ®Google Scholar
• Yoneda K, Chikaishi Y, Kuwata T, et al. Capture of mesothelioma cells with ‘universal‘ CTC-chip. Oncol Lett. 2018 Feb;15(2):2635–2640.
   PubMed Web of Science ®Google Scholar
• Yoneda K, Kuwata T, Chikaishi Y, et al. Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma. Cancer Sci. 2018 Nov;30.
   Google Scholar
• Hylebos M, Op de Beeck K, Pauwels P, et al. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients. Lung Cancer. 2018 Oct;124:19–22.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Bard MP, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol. 2004 May;164(5):1807–1815.
   PubMed Web of Science ®Google Scholar
• Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J Thorac Oncol. 2018 Jul;13(7):1012–1021.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143–e52.
   PubMed Web of Science ®Google Scholar
• Fear VS, Tilsed C, Chee J, et al. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology. 2018;7(10):e1494111.
   PubMed Web of Science ®Google Scholar
• Wu L, Wu MO, De la Maza L, et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget. 2015 May 20;6(14):12468–12480.
   PubMedGoogle Scholar
• Lesterhuis WJ, Rinaldi C, Jones A, et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Sci Rep. 2015;5:12298.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Bosco A, Millward MJ, et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov. 2017 Apr;16(4):264–272.
   PubMed Web of Science ®Google Scholar